myeloma

2022 ASCO Annual Meeting; #ASCO22
June 5, 2022
Leslie Fannon Zhang, ASCO staff

2022 ASCO Annual Meeting: Advances in Treating Breast Cancer, Colorectal Cancer, Ewing Sarcoma, and Multiple Myeloma

English
Leslie.Fannon.Zhang

The ASCO Annual Meeting is being held June 3 to 7, and here is some of the notable research that will be presented today. Topics include advances in treating HER2-low metastatic breast cancer, RAS wild-type metastatic colorectal cancer, recurrent and refractory Ewing sarcoma, and newly diagnosed multiple myeloma.

Read More >>
2019 ASCO ® Annual Meeting; #ASCO19
June 2, 2019
Monika Sharda, ASCO staff

ASCO Annual Meeting 2019: Treatment Advances for Metastatic Prostate Cancer and Pancreatic Cancer, Multiple Myeloma Survival Factors, and Effects of the Affordable Care Act on Cancer Care

English
Monika.Sharda

The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include an effective medication for metastatic prostate cancer, targeted therapy that slows the growth of metastatic pancreatic cancer, how socioeconomic factors may affect survival for multiple myeloma, and how the ACA resulted in earlier treatment and improved equality in care.

Read More >>
2019 ASCO ® Annual Meeting; #ASCO19
May 15, 2019
Greg Guthrie, ASCO staff

ASCO Annual Meeting 2019: An Early Look at This Year’s Research

English
gregguthrie

Read research highlights that will be presented at the 2019 ASCO Annual Meeting, covering low-fat diets and risk of breast cancer death, chemotherapy for older adults with esophageal cancer, targeted therapy for those at risk for multiple myeloma, the rate of genetic changes in childhood cancers, and a new targeted therapy for childhood central nervous system tumors.

Read More >>
American Society of Clinical Oncology; Clinical Cancer Advances 2018: ASCO's Annual Report on Progress Against Cancer
January 30, 2018
Greg Guthrie, ASCO staff

CAR T-Cell Immunotherapy: The 2018 Advance of the Year

English
gregguthrie

The 2018 Clinical Cancer Advances report of the American Society of Clinical Oncology has crowned an adoptive cell immunotherapy as its Advance of the Year. What is this innovative cancer treatment? What are the risks and benefits?

Read More >>
2017 ASCO Annual Meeting. #ASCO17
June 5, 2017
Greg Guthrie, ASCO staff

ASCO Annual Meeting 2017: Advances in Immunotherapy for Multiple Myeloma and Mesothelioma, and Targeted Therapies for Non-Small Cell Lung Cancer and HER2-Positive Breast Cancer

English
gregguthrie

Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Today’s key research highlights include CAR T-cell therapy for multiple myeloma, immune checkpoint inhibitors for mesothelioma, and targeted therapy advances for non-small cell lung cancer and HER2-positive breast cancer.

Read More >>

Pages

Subscribe to RSS - myeloma